Search

Your search keyword '"Mazzaferro, A"' showing total 7,043 results
Start Over Author "Mazzaferro, A"
7,043 results on '"Mazzaferro, A"'

6. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome.

Author

Berardi, Giammauro, Cucchetti, Alessandro, Sposito, Carlo, Ratti, Francesca, Nebbia, Martina, DSouza, Daniel, Pascual, Franco, Dogeas, Epameinondas, Tohme, Samer, Vitale, Alessandro, DAmico, Francesco, Alessandris, Remo, Panetta, Valentina, Simonelli, Ilaria, Colasanti, Marco, Russolillo, Nadia, Moro, Amika, Fiorentini, Guido, Serenari, Matteo, Rotellar, Fernando, Zimitti, Giuseppe, Famularo, Simone, Ivanics, Tommy, Donando, Felipe, Hoffman, Daniel, Onkendi, Edwin, Essaji, Yasmin, Giuliani, Tommaso, Lopez Ben, Santiago, Caula, Celia, Rompianesi, Gianluca, Chopra, Asmita, Abu Hilal, Mohammed, Sapisochin, Gonzalo, Torzilli, Guido, Corvera, Carlos, Alseidi, Adnan, Helton, Scott, Troisi, Roberto, Simo, Kerri, Conrad, Claudius, Cescon, Matteo, Cleary, Sean, Kwon, David, Ferrero, Alessandro, Ettorre, Giuseppe, Cillo, Umberto, Geller, David, Cherqui, Daniel, Serrano, Pablo, Ferrone, Cristina, Aldrighetti, Luca, Kingham, T, and Mazzaferro, Vincenzo

Subjects
Hepatocellular carcinoma, Metabolic syndrome, Metabolic-associated fatty liver disease, Nonalcoholic fatty liver disease, Obesity, Recurrence, Steatosis
Abstract

BACKGROUND & AIMS: Metabolic syndrome (MS) is a growing epidemic and a risk factor for the development of hepatocellular carcinoma (HCC). This study investigated the long-term outcomes of liver resection (LR) for HCC in patients with MS. Rates, timing, patterns, and treatment of recurrences were investigated, and cancer-specific survivals were assessed. METHODS: Between 2001 and 2021, data from 24 clinical centers were collected. Overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival were analyzed as well as recurrence patterns and treatment. The analysis was conducted using a competing-risk framework. The trajectory of the risk of recurrence over time was applied to a competing risk analysis. For post-recurrence survival, death resulting from tumor progression was the primary endpoint, whereas deaths with recurrence relating to other causes were considered as competing events. RESULTS: In total, 813 patients were included in the study. Median OS was 81.4 months (range 28.1-157.0 months), and recurrence occurred in 48.3% of patients, with a median RFS of 39.8 months (range 15.7-174.7 months). Cause-specific hazard of recurrence showed a first peak 6 months (0.027), and a second peak 24 months (0.021) after surgery. The later the recurrence, the higher the chance of receiving curative intent approaches (p = 0.001). Size >5 cm, multiple tumors, microvascular invasion, and cirrhosis were independent predictors of recurrence showing a cause-specific hazard over time. RFS was associated with death for recurrence (hazard ratio: 0.985, 95% CI: 0.977-0.995; p = 0.002). CONCLUSIONS: Patients with MS undergoing LR for HCC have good long-term survival. Recurrence occurs in 48% of patients with a double-peak incidence and time-specific hazards depending on tumor-related factors and underlying disease. The timing of recurrence significantly impacts survival. Surveillance after resection should be adjusted over time depending on risk factors. IMPACT AND IMPLICATIONS: Metabolic syndrome (MS) is a growing epidemic and a significant risk factor for the development of hepatocellular carcinoma (HCC). The present study demonstrated that patients who undergo surgical resection for HCC on MS have a good long-term survival and that recurrence occurs in almost half of the cases with a double peak incidence and time-specific hazards depending on tumor-related factors and underlying liver disease. Also, the timing of recurrence significantly impacts survival. Clinicians should therefore adjust follow-up after surgery accordingly, considering timing of recurrence and specific risk factors. Also, the results of the present study might help design future trials on the use of adjuvant therapy following resection.

Published
2024

7. Good rates from bad coordinates: the exponential average time-dependent rate approach

Author

Mazzaferro, Nicodemo, Sasmal, Subarna, Cossio, Pilar, and Hocky, Glen M.

Subjects
Physics - Chemical Physics, Condensed Matter - Statistical Mechanics, Physics - Biological Physics
Abstract

Our ability to calculate rates of biochemical processes using molecular dynamics simulations is severely limited by the fact that the time scales for reactions, or changes in conformational state, scale exponentially with the relevant free-energy barriers. In this work, we improve upon a recently proposed rate estimator that allows us to predict transition times with molecular dynamics simulations biased to rapidly explore one or several collective variables. This approach relies on the idea that not all bias goes into promoting transitions, and along with the rate, it estimates a concomitant scale factor for the bias termed the collective variable biasing efficiency $\gamma$. First, we demonstrate mathematically that our new formulation allows us to derive the commonly used Infrequent Metadynamics (iMetaD) estimator when using a perfect collective variable, $\gamma=1$. After testing it on a model potential, we then study the unfolding behavior of a previously well characterized coarse-grained protein, which is sufficiently complex that we can choose many different collective variables to bias, but which is sufficiently simple that we are able to compute the unbiased rate dire ctly. For this system, we demonstrate that our new Exponential Average Time-Dependent Rate (EATR) estimator converges to the true rate more rapidly as a function of bias deposition time than does the previous iMetaD approach, even for bias deposition times that are short. We also show that the $\gamma$ parameter can serve as a good metric for assessing the quality of the biasing coordinate. Finally, we demonstrate that the approach works when combining multiple less-than-optimal bias coordinates., Comment: 14 pages, 5 figures; 4 pages of supporting information with 2 tables and 6 additional figures

Published
2024

8. Cornerstones and divergencies in the implementation and use of liver hypertrophy techniques: results from a nationwide survey for the set-up of the prospective registry

Author

Ratti, Francesca, Serenari, Matteo, Avolio, Alfonso, Batignani, Giacomo, Boggi, Ugo, Brolese, Alberto, Caccamo, Lucio, Celotti, Andrea, Cillo, Umberto, Cinardi, Nicola, Cotsoglou, Christian, Dalla Valle, Raffaele, De Carlis, Luciano, De Simone, Paolo, Di Benedetto, Fabrizio, Ercolani, Giorgio, Ettorre, Giuseppe Maria, Fedi, Massimo, Ferrero, Alessandro, Giuliani, Antonio, Giuliante, Felice, Grazi, Gian Luca, Gruttadauria, Salvatore, Guglielmi, Alfredo, Izzo, Francesco, Lai, Quirino, Lorenzin, Dario, Maestri, Marcello, Massani, Marco, Mazzaferro, Vincenzo, Memeo, Riccardo, Nardo, Bruno, Portolani, Nazario, Ravaioli, Matteo, Rocca, Aldo, Romagnoli, Renato, Romano, Fabrizio, Saladino, Edoardo, Tisone, Giuseppe, Troisi, Roberto, Veneroni, Luigi, Vennarecci, Giovanni, Viganò, Luca, Viola, Giuseppe, Vivarelli, Marco, Zanus, Giacomo, Aldrighetti, Luca, and Jovine, Elio

Published
2024
Full Text
View/download PDF

9. Factors Associated with and Impact of Open Conversion in Laparoscopic and Robotic Minor Liver Resections: An International Multicenter Study of 10,541 Patients

Author

Saleh, Mansour, Pascual, Franco, Ghallab, Mohammed, Wu, Andrew G. R., Chin, Ken-Min, Ratti, Francesca, Giglio, Mariano Cesare, Garatti, Marco, Nghia, Phan Phuoc, Kato, Yutaro, Lim, Chetana, Herman, Paulo, Coelho, Fabricio Ferreira, Schmelzle, Moritz, Pratschke, Johann, Aghayan, Davit L., Liu, Qiu, Marino, Marco V., Belli, Andrea, Chiow, Adrian K. H., Sucandy, Iswanto, Ivanecz, Arpad, Di Benedetto, Fabrizio, Choi, Sung Hoon, Lee, Jae Hoon, Park, James O., Prieto, Mikel, Guzman, Yoelimar, Fondevila, Constantino, Efanov, Mikhail, Rotellar, Fernando, Choi, Gi-Hong, Robles-Campos, Ricardo, Kadam, Prashant, Sutcliffe, Robert P., Troisi, Roberto I., Tang, Chung Ngai, Chong, Charing C., D’Hondt, Mathieu, Dalla Valle, Bernardo, Ruzzenente, Andrea, Kingham, T. Peter, Scatton, Olivier, Liu, Rong, Mejia, Alejandro, Mishima, Kohei, Wakabayashi, Go, Lopez-Ben, Santiago, Wang, Xiaoying, Ferrero, Alessandro, Ettorre, Giuseppe Maria, Vivarelli, Marco, Mazzaferro, Vincenzo, Giuliante, Felice, Yong, Chee Chien, Yin, Mengqiu, Monden, Kazuteru, Geller, David, Chen, Kuo-Hsin, Sugioka, Atsushi, Edwin, Bjørn, Cheung, Tan-To, Long, Tran Cong Duy, Abu Hilal, Mohammad, Aldrighetti, Luca, Soubrane, Olivier, Fuks, David, Han, Ho-Seong, Cherqui, Daniel, and Goh, Brian K. P.

Published
2024
Full Text
View/download PDF

11. The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives

Author

Gringeri, Enrico, Furlanetto, Alessandro, Billato, Ilaria, Cescon, Matteo, De Carlis, Luciano, Mazzaferro, Vincenzo, Romagnoli, Renato, De Simone, Paolo, Vivarelli, Marco, Di Benedetto, Fabrizio, Ravaioli, Matteo, Lauterio, Andrea, Sposito, Carlo, Patrono, Damiano, Ghinolfi, Davide, Moccheggiani, Federico, Di Sandro, Stefano, D’Amico, Francesco Enrico, Lanari, Jacopo, Gambato, Martina, Trapani, Silvia, Bergamo, Francesca, Cardillo, Massimo, Burra, Patrizia, and Cillo, Umberto

Published
2024
Full Text
View/download PDF

14. Whitepaper on Reusable Hybrid and Multi-Cloud Analytics Service Framework

Author

von Laszewski, Gregor, Chang, Wo, Reinsch, Russell, Kotevska, Olivera, Karimi, Ali, Sattar, Abdul Rahman, Mazzaferro, Garry, and Fox, Geoffrey C.

Subjects
Computer Science - Distributed, Parallel, and Cluster Computing
Abstract

Over the last several years, the computation landscape for conducting data analytics has completely changed. While in the past, a lot of the activities have been undertaken in isolation by companies, and research institutions, today's infrastructure constitutes a wealth of services offered by a variety of providers that offer opportunities for reuse, and interactions while leveraging service collaboration, and service cooperation. This document focuses on expanding analytics services to develop a framework for reusable hybrid multi-service data analytics. It includes (a) a short technology review that explicitly targets the intersection of hybrid multi-provider analytics services, (b) a small motivation based on use cases we looked at, (c) enhancing the concepts of services to showcase how hybrid, as well as multi-provider services can be integrated and reused via the proposed framework, (d) address analytics service composition, and (e) integrate container technologies to achieve state-of-the-art analytics service deployment

Published
2023

15. Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

Author

Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Rafaella, Arcangeli, Giuseppina, Corallo, Salvatore, Delliponti, Laura, Tamberi, Stefano, Fea, Elena, Brandi, Giovanni, Rapposelli, Ilario Giovanni, Salati, Massimiliano, Baili, Paolo, Miceli, Rosalba, Ljevar, Silva, Cavallo, Ilaria, Sottotetti, Elisa, Martinetti, Antonia, Busset, Michele Droz Dit, Sposito, Carlo, Di Bartolomeo, Maria, Pietrantonio, Filippo, de Braud, Filippo, and Mazzaferro, Vincenzo

Published
2024
Full Text
View/download PDF

16. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Author

Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Raffaella, Arcangeli, Giuseppina, Corallo, Salvatore, Delliponti, Laura, Tamberi, Stefano, Fea, Elena, Brandi, Giovanni, Rapposelli, Ilario Giovanni, Salati, Massimiliano, Baili, Paolo, Miceli, Rosalba, Ljevar, Silva, Cavallo, Ilaria, Sottotetti, Elisa, Martinetti, Antonia, Busset, Michele Droz Dit, Sposito, Carlo, Di Bartolomeo, Maria, Pietrantonio, Filippo, de Braud, Filippo, and Mazzaferro, Vincenzo

Published
2024
Full Text
View/download PDF

18. Social support and help-seeking worldwide

Author

Szkody, Erica, Spence, Anjolee, Özdoğru, Asil, Tushir, Bhawna, Chang, Fennie, AKKAŞ, Handan, Sotomayor, Ian, Pavlova, Iuliia, Petrovic, Ivana, Norvilitis, Jill, Pena-Shaff, Judith, Maney, Julia, Arrow, Kaitlyn, Rodriguez, Laura, Moussa-Rogers, Mary, McTighe, Michael, Ogba, Kalu T. U., Yeung, Stephanie Ka Wai Au, Stoppa, Tara, Yang, Yuanyuan, Gosnell, Courtney L., Jérémie-Brink, Gihane, Van Nostrand, Joshua J., Arriaga, Patrícia, Martin, Amy, Maksimovic, Ana, Ursu, Andreea, Karakulak, Arzu, Fitapelli, Brianna, Ashdown, Brien K., Sen, Celia K. Naivar, Chartier, Chris, Shane-Simpson, Christina, Redker, Christopher M., McKinney, Cliff, Baro, Danisha, Manrique-Millones, Denisse, Reis, Eduardo Silva, Adamopoulou, Eirini, Volkan, Eliz, Tair, Ergyul, Trujillo, Ethan, Kocalar, Halil Emre, Blocker, Heidi, Malik, Hinza, Orta, İrem Metin, Santos, Jay Claus, Grahe, Jon, Cuccolo, Kelly, Wignall, Liam, McLain, Malorie, Kosic, Marianna, Aita, Moet, Nash, Monique, Miracle, Ogba Oluchi, Christiano, Olivia, Dimitrova, Radosveta, Varma, Rahul, Mann, Rebecca, Dhakal, Sandesh, Estrada-Villalta, Sara, Haden, Sara, Hamilton, Sarah, Camgöz, Selin Metin, Aljuberi, Shams, Chin, Stephanie, Kohn, Steven, Verma, Sunil K., Fletcher, Tifani, Singh, Tushar, Sanders, Abigail, Collado, Adryana, Adusei, Akua, Itani, Alaa, Kaser, Amanda, Wolfe, Amber, Stout, Amy, Akhavan, Anahita, Kirton, Angelique, Çeçen-Eroğul, Ayşe Rezan, Bilir, Bilge, Dupiton, Camille, Lovett, Caroline, Orsini, Chloe, Kpodo, Christney, Aceto, Christopher, Redden, Clare, NyKanen, Danielle, Yildiz, Deniz, Lutringer, Emily, Sevinç, Ender, Baranski, Erica, Khan, Fahd, Jia, Fanli, Cramariuc, Gabriel, Zhang, Guolin, Resulbegoviq, Hakile, Maree, Haneen, Kaur, Harleen, Nelson, Jessie, Espinoza, Jimena Santa Cruz, Hubbard, JoAnna, Edlund, John, Protzko, John, Hoang, Jolie, Stork, Jordan, Vasu, Jordan, Salazar, Jose Verdis, Myhers, Karyssa, Hayward, Kaylynn, Lu, Kevin, Beardmore, Leisha, Levkiv, Liliia, Godoy, Linda Katheryn Hernandez, Paulett, Liseth, Gonzalez, María Fernanda Bonilla, Kalantzis, Maria, Rodrigues, Mariana, Álvarez, Marinés Mejía, Ott, Marissa, Zlokovich, Martha, Brosnan, Mary Kate, Mazzaferro, Mateus, Yetkin, Melis, Johnson, Mikayla, Vukelic, Milica, Clark, Mitchell, AlMalik, Mohammad, Fedavi, Neda, Means-Simonsen, Noah, Cabrera, Onassis, Kovacevic, Panta, Zhang, Qingyi, Rushing, Rachel, Varakis, Rafail, Richardson, Randall, Koch, Sara, Lewis, Savannah, Barrera, Scott, Zheng, Sifan, Liu, Siyu, Papka, Sophia, Das, Sreeja, Ghimire, Srijana, Verma, Tanya, Hillman, Taylor, Ozkusen, Ugur C., Zhang, Xinyi (Spencer), Gu, Yiwen, Redd, Bryce, and Cascalheira, Cory J.

Published
2024
Full Text
View/download PDF

20. Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology

Author

Maen Abdelrahim, Abdullah Esmail, Taizo Hibi, and Vincenzo Mazzaferro

Subjects
immunotherapy, liver transplantation, transplant oncology, ctDNA, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Transplant oncology is an expanding area of cancer therapy that specifically emphasizes the use of liver transplantation (LT) as the preferred treatment for patients with manageable, but unresectable, tumors. The management and optimization of overall survival strategies, accompanied by an arguably decent quality of life, have been at the forefront of liver oncology treatment, as a plurality of all primary liver cancers are identified as either hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), which are classified as highly aggressive malignancies and frequently remain asymptomatic until they progress to advanced stages, rendering curative procedures, such as resection, impractical. This has led to an increase in utilization of neoadjuvant interventions conducted prior to surgery, which has yielded favorable outcomes. Though this treatment modality has prompted further investigations into the efficacy of immune checkpoint inhibitors (ICPIs) as standalone treatments and in combination with locoregional treatments (LRTs) to bridge more patients into curative eligibility. This multidisciplinary methodology and treatment planning has seen multiple successful trials of immunotherapy regimes and combinate treatments, setting the groundwork for increasing eligibility through downstaging and “bridging” previously ineligible patients within stringent LT criteria. Surveillance after LT is a crucial component of transplant oncology. The emergence of circulating tumor DNA (ctDNA) has provided a novel approach to identifying the recurrence of cancer in its early stages. Recent research has focused on liquid biopsy, a technique that effectively identifies the dynamics of cancer. This is another innovation to demonstrate the rate at which transplant oncology is rapidly advancing, making the focus of care feel disorienting. Modalities of care are constantly evolving, but when a field is changing as rapidly as this one, it is imperative to reorient to the data and the needs of the patients. In this commentary, we reflect on the update’s utilization of ICPIs in neoadjuvant settings as well as the updates on the utilization of liquid biopsy in post-LT follow-up surveillance.

Published
2024
Full Text
View/download PDF

21. Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study

Author

Marianna Maspero, Carlo Sposito, Marco A. Bongini, Tommaso Cascella, Maria Flores, Marco Maccauro, Carlo Chiesa, Monica Niger, Filippo Pietrantonio, Giuseppe Leoncini, Valentina Bellia, Sherrie Bhoori, and Vincenzo Mazzaferro

Subjects
biliary tract cancers, downstaging, gemcitabine-cisplatin, Yttrium-90, tare, Specialties of internal medicine, RC581-951
Abstract

Liver transplantation (LT) is a potentially curative experimental treatment for unresectable intrahepatic cholangiocarcinoma (iCC). Pre-transplant downstaging may help defining tumor aggressiveness and drive patient selection. We report the preliminary results of LT for liver-limited unresectable iCC after sequential downstaging with systemic chemotherapy and radioembolization (SYS-TARE). In case of sustained disease stability after SYS-TARE, patients underwent surgical nodal sampling and, if negative, were listed for LT. In this study, 13 patients with unresectable iCC underwent downstaging with SYS-TARE. The median age was 70 years and 77% were female. All had single bulky lesions at diagnosis. After SYS-TARE, 9 (69%) dropped out: 3 due to progressive disease after TARE with no response to second-line, 4 due to extrahepatic disease development and 2 due to positive nodal disease at pre-listing abdominal exploration. The median OS after dropout was 11.5 months. Four (31%) were successfully listed and transplanted. At pathology, viable tumor ranged from 30% to less than 5%. All four patients are alive and disease-free at 73, 40, 12, and 8 months from LT. LT for unresectable iCC after downstaging with SYS-TARE appears to select suitable patients for LT, achieving optimal oncological outcomes in case of response to therapy and no lymphnodal spread.

Published
2024
Full Text
View/download PDF

23. Impact of Liver Cirrhosis, Severity of Cirrhosis, and Portal Hypertension on the Difficulty and Outcomes of Laparoscopic and Robotic Major Liver Resections for Primary Liver Malignancies

Author

Cipriani, Federica, Aldrighetti, Luca, Ratti, Francesca, Wu, Andrew G. R., Kabir, Tousif, Scatton, Olivier, Lim, Chetana, Zhang, Wanguang, Sijberden, Jasper, Aghayan, Davit L., Siow, Tiing-Foong, Dokmak, Safi, Coelho, Fabricio Ferreira, Herman, Paulo, Marino, Marco V., Mazzaferro, Vincenzo, Chiow, Adrian K. H., Sucandy, Iswanto, Ivanecz, Arpad, Choi, Sung-Hoon, Lee, Jae Hoon, Gastaca, Mikel, Vivarelli, Marco, Giuliante, Felice, Ruzzenente, Andrea, Yong, Chee-Chien, Yin, Mengqiu, Fondevila, Constantino, Efanov, Mikhail, Morise, Zenichi, Di Benedetto, Fabrizio, Brustia, Raffaele, Dalla Valle, Raffaele, Boggi, Ugo, Geller, David, Belli, Andrea, Memeo, Riccardo, Gruttadauria, Salvatore, Mejia, Alejandro, Park, James O., Rotellar, Fernando, Choi, Gi-Hong, Robles-Campos, Ricardo, Wang, Xiaoying, Sutcliffe, Robert P., Pratschke, Johann, Lai, Eric C. H., Chong, Charing C. N., D’Hondt, Mathieu, Monden, Kazuteru, Lopez-Ben, Santiago, Kingham, T. Peter, Ferrero, Alessandro, Ettorre, Giuseppe Maria, Cherqui, Daniel, Liang, Xiao, Soubrane, Olivier, Wakabayashi, Go, Troisi, Roberto I., Cheung, Tan-To, Kato, Yutaro, Sugioka, Atsushi, Han, Ho-Seong, Long, Tran Cong duy, Liu, Qu, Liu, Rong, Edwin, Bjørn, Fuks, David, Chen, Kuo-Hsin, Abu Hilal, Mohammad, and Goh, Brian K. P.

Published
2024
Full Text
View/download PDF

24. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Author

Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano, Federica Palermo, Lorenza Rimassa, Tiziana Pressiani, Rossana Berardi, Andrea Casadei Gardini, Elisa Sperti, Lisa Salvatore, Davide Melisi, Francesca Bergamo, Salvatore Siena, Stefania Mosconi, Raffaella Longarini, Giuseppina Arcangeli, Salvatore Corallo, Laura Delliponti, Stefano Tamberi, Elena Fea, Giovanni Brandi, Ilario Giovanni Rapposelli, Massimiliano Salati, Paolo Baili, Rosalba Miceli, Silva Ljevar, Ilaria Cavallo, Elisa Sottotetti, Antonia Martinetti, Michele Droz Dit Busset, Carlo Sposito, Maria Di Bartolomeo, Filippo Pietrantonio, Filippo de Braud, and Vincenzo Mazzaferro

Subjects
Biliary tract cancers, Cholangiocarcinoma, Neoadjuvant chemotherapy, Cisplatin gemcitabine nabpaclitaxel, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1–3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, the 5-year survival rate after radical surgery (R0) is 20–40% and recurrence rates are up to ~ 75%(4–6). Up to ~ 40% of patients relapse within 12 months after resection, and half of these patient will recur systemically(4–6). There is no standard of care for neoadjuvant chemotherapy (NAC) in resectable BTC, but retrospective reports suggest its potential benefit (7, 8). Methods PURITY is a no-profit, multicentre, randomized phase II/III trial aimed at evaluating the efficacy of the combination of gemcitabine, cisplatin and nabpaclitaxel (GAP) as neoadjuvant treatment in patients with resectable BTC at high risk for recurrence. Primary objective of this study is to evaluate the efficacy of neoadjuvant GAP followed by surgery as compared to upfront surgery, in terms of 12-month progression-free survival for the phase II part and of progression free survival (PFS) for the phase III study. Key Secondary objectives are event free survival (EFS), relapse-free survival, (RFS), overall survival (OS), R0/R1/R2 resection rate, quality of life (QoL), overall response rate (ORR), resectability. Safety analyses will include toxicity rate and perioperative morbidity and mortality rate. Exploratory studies including Next-Generation Sequencing (NGS) in archival tumor tissues and longitudinal ctDNA analysis are planned to identify potential biomarkers of primary resistance and prognosis. Discussion Considering the poor prognosis of resected BTC experiencing early tumor recurrence and the negative prognostic impact of R1/R2 resections, PURITY study is based on the rationale that NAC may improve R0 resection rates and ultimately patients’ outcomes. Furthermore, NAC should allow early eradication of microscopic distant metastases, undetectable by imaging but already present at the time of diagnosis and avoid mortality and morbidity associated with resection for patients with rapid progression or worsening general condition during neoadjuvant therapy. The randomized PURITY study will evaluate whether patients affected by BTC at high risk from recurrence benefit from a neoadjuvant therapy with GAP regimen as compared to immediate surgery. Trial registration PURITY is registered at ClinicalTrials.gov (NCT06037980) and EuCT(2023–503295-25–00).

Published
2024
Full Text
View/download PDF

25. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome

Author

Giammauro Berardi, Alessandro Cucchetti, Carlo Sposito, Francesca Ratti, Martina Nebbia, Daniel M. D’Souza, Franco Pascual, Epameinondas Dogeas, Samer Tohme, Alessandro Vitale, Francesco Enrico D’Amico, Remo Alessandris, Valentina Panetta, Ilaria Simonelli, Marco Colasanti, Nadia Russolillo, Amika Moro, Guido Fiorentini, Matteo Serenari, Fernando Rotellar, Giuseppe Zimitti, Simone Famularo, Tommy Ivanics, Felipe Gaviria Donando, Daniel Hoffman, Edwin Onkendi, Yasmin Essaji, Tommaso Giuliani, Santiago Lopez Ben, Celia Caula, Gianluca Rompianesi, Asmita Chopra, Mohammed Abu Hilal, Gonzalo Sapisochin, Guido Torzilli, Carlos Corvera, Adnan Alseidi, Scott Helton, Roberto I. Troisi, Kerri Simo, Claudius Conrad, Matteo Cescon, Sean Cleary, David Choon Hyuck Kwon, Alessandro Ferrero, Giuseppe Maria Ettorre, Umberto Cillo, David Geller, Daniel Cherqui, Pablo E. Serrano, Cristina Ferrone, Luca Aldrighetti, T. Peter Kingham, and Vincenzo Mazzaferro

Subjects
Hepatocellular carcinoma, Metabolic syndrome, Nonalcoholic fatty liver disease, Metabolic-associated fatty liver disease, Recurrence, Steatosis, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background & Aims: Metabolic syndrome (MS) is a growing epidemic and a risk factor for the development of hepatocellular carcinoma (HCC). This study investigated the long-term outcomes of liver resection (LR) for HCC in patients with MS. Rates, timing, patterns, and treatment of recurrences were investigated, and cancer-specific survivals were assessed. Methods: Between 2001 and 2021, data from 24 clinical centers were collected. Overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival were analyzed as well as recurrence patterns and treatment. The analysis was conducted using a competing-risk framework. The trajectory of the risk of recurrence over time was applied to a competing risk analysis. For post-recurrence survival, death resulting from tumor progression was the primary endpoint, whereas deaths with recurrence relating to other causes were considered as competing events. Results: In total, 813 patients were included in the study. Median OS was 81.4 months (range 28.1–157.0 months), and recurrence occurred in 48.3% of patients, with a median RFS of 39.8 months (range 15.7–174.7 months). Cause-specific hazard of recurrence showed a first peak 6 months (0.027), and a second peak 24 months (0.021) after surgery. The later the recurrence, the higher the chance of receiving curative intent approaches (p = 0.001). Size >5 cm, multiple tumors, microvascular invasion, and cirrhosis were independent predictors of recurrence showing a cause-specific hazard over time. RFS was associated with death for recurrence (hazard ratio: 0.985, 95% CI: 0.977–0.995; p = 0.002). Conclusions: Patients with MS undergoing LR for HCC have good long-term survival. Recurrence occurs in 48% of patients with a double-peak incidence and time-specific hazards depending on tumor-related factors and underlying disease. The timing of recurrence significantly impacts survival. Surveillance after resection should be adjusted over time depending on risk factors. Impact and implications: Metabolic syndrome (MS) is a growing epidemic and a significant risk factor for the development of hepatocellular carcinoma (HCC). The present study demonstrated that patients who undergo surgical resection for HCC on MS have a good long-term survival and that recurrence occurs in almost half of the cases with a double peak incidence and time-specific hazards depending on tumor-related factors and underlying liver disease. Also, the timing of recurrence significantly impacts survival. Clinicians should therefore adjust follow-up after surgery accordingly, considering timing of recurrence and specific risk factors. Also, the results of the present study might help design future trials on the use of adjuvant therapy following resection.

Published
2024
Full Text
View/download PDF

26. Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH

Author

Ankoor H. Patel, Gaurav N. Pathak, Alexander Chen, Patricia Greenberg, Natale Mazzaferro, Anish Patel, Naveen Mallangada, Carlos D. Minacapelli, Kaitlyn Catalano, Hansel Suthar, and Vinod K. Rustgi

Subjects
Clostridioides difficile, Nonalcoholic fatty liver disease, Mortality, Nonalcoholic steatohepatitis, Specialties of internal medicine, RC581-951
Abstract

Introduction and Objectives: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and can progress to non-alcoholic steatohepatitis (NASH) and, ultimately, cirrhosis. Clostridioides difficile is the most common nosocomial cause of diarrhea and is associated with worse clinical outcomes in other liver diseases, including cirrhosis, but has not been extensively evaluated in concomitant NAFLD/NASH. Materials and Methods: We conducted a retrospective cohort study using the National Inpatient Sample database from 2015 to 2017. Patients with a diagnosis of CDI, NAFLD, and NASH were identified using International Classification of Diseases (Tenth Revision) codes. The outcomes of our study include length of stay, hospitalization cost, mortality, and predictors of mortality. Results: The CDI and NASH cohort had a higher degree of comorbidity burden and prevalence of peptic ulcer disease, congestive heart failure, diabetes mellitus, and cirrhosis. Patients with NASH and CDI had a significantly higher mortality rate compared to the CDI only cohort (mortality, 7.11 % vs. 6.36 %; P = 0.042). Patients with CDI and NASH were at increased risk for liver-related complications, acute kidney injury, and septic shock (P < 0.001) compared to patients with CDI only. Older age, intestinal complications, pneumonia, sepsis and septic shock, and liver failure conferred an increased risk of mortality among the CDI and NASH cohort. Conclusions: Patients with NASH had a higher rate of liver-related complications, progression to septic shock, and mortality rate following CDI infection compared to the CDI only cohort.

Published
2024
Full Text
View/download PDF

30. In vitro Evaluation of the Calcification Inhibitory Properties of Policosanol, Genistein, and Vitamin D (Reduplaxin®) either Alone or in Combination

Author

Carla Iacobini, Valeria Fassino, Sandro Mazzaferro, and Lida Tartaglione

Subjects
vascular calcification, vitamin d, policosanol, genistein, vascular smooth muscle cells trans-differentiation, Dermatology, RL1-803, Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Introduction: The process of vascular calcification has severe clinical consequences in a number of diseases, including diabetes, atherosclerosis, and end-stage renal disease. In the present study, we investigated the effect of policosanol (Poli), genistein (Gen), and vitamin D (VitD) separately and in association to evaluate the possible synergistic action on inorganic phosphate (Pi)-induced calcification of vascular smooth muscle cells (VSMCs). Methods: Primary human VSMCs were cultured with either growth medium or growth medium supplemented with calcium and phosphorus (calcification medium) in combination with Poli, Gen, and VitD. Alizarin Red staining, mineralization, and the protein expression of RUNX2 and superoxide dismutase-2 (SOD2) were investigated. Results: All three substances tested were effective at reducing osteogenic differentiation of VSMCs in a dose-dependent manner. Poli+Gen, Poli+VitD, Gen+VitD treatment induced a greater inhibition of calcification and RUNX2 expression compared to single compounds treatments. Moreover, the association of Poli+Gen+VitD (Reduplaxin®) was more effective at inhibiting VSMCs mineralization and preventing the increase in RUNX2 expression induced by calcification medium but not modified SOD2 expression. Conclusions: The association of Pol, Gen, and VitD (Reduplaxin®) has an additive inhibitory effect on the calcification process of VSMCs induced in vitro by a pro-calcifying medium.

Published
2024
Full Text
View/download PDF

33. Impact of Tumor Size on the Difficulty of Laparoscopic Major Hepatectomies: An International Multicenter Study

Author

Kato, Yutaro, Sugioka, Atsushi, Kojima, Masayuki, Syn, Nicholas L., Zhongkai, Wang, Liu, Rong, Cipriani, Federica, Armstrong, Thomas, Aghayan, Davit L., Siow, Tiing-Foong, Lim, Chetana, Scatton, Olivier, Herman, Paulo, Coelho, Fabricio Ferreira, Marino, Marco V., Mazzaferro, Vincenzo, Chiow, Adrian K. H., Sucandy, Iswanto, Ivanecz, Arpad, Choi, Sung Hoon, Lee, Jae Hoon, Gastaca, Mikel, Vivarelli, Marco, Giuliante, Felice, Dalla Valle, Bernardo, Ruzzenente, Andrea, Yong, Chee-Chien, Fondevila, Constantino, Efanov, Mikhail, Di Benedetto, Fabrizio, Belli, Andrea, Park, James O., Rotellar, Fernando, Choi, Gi-Hong, Robles-Campos, Ricardo, Wang, Xiaoying, Sutcliffe, Robert P., Schmelzle, Moritz, Pratschke, Johann, Lai, Eric C. H., Chong, Charing C. N., D’Hondt, Mathieu, Monden, Kazuteru, Lopez-Ben, Santiago, Kingham, T. Peter, Forchino, Fabio, Ferrero, Alessandro, Ettorre, Giuseppe Maria, Levi Sandri, Giovanni Battista, Pascual, Franco, Cherqui, Daniel, Soubrane, Olivier, Wakabayashi, Go, Troisi, Roberto I., Cheung, Tan-To, Chen, Zewei, Yin, Mengqiu, D’Silva, Mizelle, Han, Ho-Seong, Nghia, Phan Phuoc, Long, Tran Cong duy, Edwin, Bjørn, Fuks, David, Chen, Kuo-Hsin, Abu Hilal, Mohammad, Aldrighetti, Luca, and Goh, Brian K. P.

Published
2023
Full Text
View/download PDF

35. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer

Author

Boggi, Ugo, Kauffmann, Emanuele, Napoli, Niccolò, Barreto, S. George, Besselink, Marc G., Fusai, Giuseppe K., Hackert, Thilo, Abu Hilal, Mohammad, Marchegiani, Giovanni, Salvia, Roberto, Shrikhande, Shailesh V., Truty, Mark, Werner, Jens, Wolfgang, Christopher L., Bannone, Elisa, Capretti, Giovanni, Cattelani, Alice, Coppola, Alessandro, Cucchetti, Alessandro, De Sio, Davide, Di Dato, Armando, Di Meo, Giovanna, Fiorillo, Claudio, Gianfaldoni, Cesare, Ginesini, Michael, Hidalgo Salinas, Camila, Lai, Quirino, Miccoli, Mario, Montorsi, Roberto, Pagnanelli, Michele, Poli, Andrea, Ricci, Claudio, Sucameli, Francesco, Tamburrino, Domenico, Viti, Virginia, Addeo, Pietro F., Alfieri, Sergio, Bachellier, Philippe, Baiocchi, Gian Luca, Balzano, Gianpaolo, Barbarello, Linda, Brolese, Alberto, Busquets, Juli, Butturini, Giovanni, Caniglia, Fabio, Caputo, Damiano, Casadei, Riccardo, Chunhua, Xi, Colangelo, Ettore, Coratti, Andrea, Costa, Francesca, Crafa, Francesco, Dalla Valle, Raffaele, De Carlis, Luciano, de Wilde, Roeland F., Del Chiaro, Marco, Di Benedetto, Fabrizio, Di Sebastiano, Pierluigi, Dokmak, Safi, Hogg, Melissa, Egorov, Vyacheslav I., Ercolani, Giorgio, Ettorre, Giuseppe Maria, Falconi, Massimo, Ferrari, Giovanni, Ferrero, Alessandro, Filauro, Marco, Giardino, Alessandro, Grazi, Gian Luca, Gruttadauria, Salvatore, Izbicki, Jakob R, Jovine, Elio, Katz, Matthew, Keck, Tobias, Khatkov, Igor, Kiguchi, Gozo, Kooby, David, Lang, Hauke, Lombardo, Carlo, Malleo, Giuseppe, Massani, Marco, Mazzaferro, Vincenzo, Memeo, Riccardo, Miao, Yi, Mishima, Kohei, Molino, Carlo, Nagakawa, Yuichi, Nakamura, Masafumi, Nardo, Bruno, Panaro, Fabrizio, Pasquali, Claudio, Perrone, Vittorio, Rangelova, Elena, Liu, Rong, Romagnoli, Renato, Romito, Raffaele, Rosso, Edoardo, Schulick, Richard, Siriwardena, Ajith, Spampinato, Marcello Giuseppe, Strobel, Oliver, Testini, Mario, Troisi, Roberto Ivan, Uzunoglo, Faik G., Valente, Roberto, Veneroni, Luigi, Zerbi, Alessandro, Vicente, Emilio, Vistoli, Fabio, Vivarelli, Marco, Wakabayashi, Go, Zanus, Giacomo, Zureikat, Amer, Zyromski, Nicholas J., Coppola, Roberto, D’Andrea, Vito, Davide, José, Dervenis, Christos, Frigerio, Isabella, Konlon, Kevin C., Michelassi, Fabrizio, Montorsi, Marco, Nealon, William, Portolani, Nazario, Sousa Silva, Donzília, Bozzi, Giuseppe, Ferrari, Viviana, Trivella, Maria G., Cameron, John, Clavien, Pierre-Alain, Asbun, Horacio J., Boraschi, Piero, Campani, Daniela, Cappelli, Carla, Cioni, Roberto, Dominici, Massimo, Esposito, Irene, Gambacorta, Maria A, Marciano, Emanuele, Masi, Gianluca, Morganti, Alessio, Mutignani, Massimiliano, Neri, Emanuele, Paiar, Fabiola, Reni, Michele, Rotondo, Maria Isabella, Silvestris, Nicola, Tortora, Giampaolo, Vasile, Enrico, and Volterrani, Duccio

Published
2024
Full Text
View/download PDF

36. Probability of lymph node metastases in patients undergoing adequate lymphadenectomy during surgery for intrahepatic cholangiocarcinoma: a retrospective multicenter study

Author

Carlo Sposito, Alessandro Cucchetti, Francesca Ratti, Laura Alaimo, Francesco Ardito, Stefano Di Sandro, Matteo Serenari, Giammauro Berardi, Marianna Maspero, Giuseppe Maria Ettorre, Matteo Cescon, Fabrizio Di Benedetto, Felice Giuliante, Andrea Ruzzenente, Giorgio Ercolani, Luca Aldrighetti, and Vincenzo Mazzaferro

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction Nodal metastases (LNM) are one of the major determinants of prognosis following surgery for intrahepatic cholangiocarcinoma (ICC). Previous studies investigating the correlation between clinical-radiological features and the probability of LNM include patients undergoing inadequate nodal sampling. Aim of this study was to develop a model to predict the risk of LNM in patients undergoing adequate lymphadenectomy using preoperative clinical and radiological features. Methods Patients undergoing radical surgery for ICC with adequate lymphadenectomy at seven Italian Centers between 2000 and 2023 were collected and divided in a derivation and a validation cohort. Logistic regression and dominance analysis were applied in the derivation cohort to identify variables associated with LNM at pathology. The final coefficients were derived from the model having the highest c-statistic in the derivation cohort with the lowest number of variables included (parsimony). The model was then tested in the external validation cohort and the linear predictor was divided into quartiles to generate four risk categories. Results A total of 693 patients were identified. Preoperative Ca19-9, clinically suspicious lymph nodes at radiology, patients’ age and tumour burden score were significantly associated with LNM. These factors were included in a model (https://aicep.website/?cff-form=20) showing a c-statistic of 0.723 (95%CI: 0.680, 0.766) and 0.771 (95%CI: 0.699, 0.842) in the derivation and validation cohort respectively. A progressive increase of pathological lymph node positivity across risk groups was observed (29.9% in low-risk, 45.1% in intermediate-low risk, 51.5% in intermediate-high risk and 87.3% in high-risk patients; p=0.001). Conclusions A novel model that combines preoperative Ca19-9, clinically suspicious lymph nodes at radiology, patients’ age and tumour burden score was developed to predict the risk of lymph node metastasis (LNM) before surgery. The model exhibited high accuracy, and has the potential to assist clinicians in the management of patients who are candidate to surgery.

Published
2024
Full Text
View/download PDF

37. Genome-wide association analyses of physical activity and sedentary behavior provide insights into underlying mechanisms and roles in disease prevention.

Author

Wang, Zhe, Emmerich, Andrew, Pillon, Nicolas, Moore, Tim, Hemerich, Daiane, Cornelis, Marilyn, Mazzaferro, Eugenia, Broos, Siacia, Ahluwalia, Tarunveer, Bartz, Traci, Bentley, Amy, Bielak, Lawrence, Chong, Mike, Chu, Audrey, Berry, Diane, Dorajoo, Rajkumar, Dueker, Nicole, Kasbohm, Elisa, Feenstra, Bjarke, Feitosa, Mary, Gieger, Christian, Graff, Mariaelisa, Hall, Leanne, Haller, Toomas, Hartwig, Fernando, Hillis, David, Huikari, Ville, Heard-Costa, Nancy, Holzapfel, Christina, Jackson, Anne, Johansson, Åsa, Jørgensen, Anja, Kaakinen, Marika, Karlsson, Robert, Kerr, Kathleen, Kim, Boram, Koolhaas, Chantal, Kutalik, Zoltan, Lagou, Vasiliki, Lind, Penelope, Lorentzon, Mattias, Lyytikäinen, Leo-Pekka, Mangino, Massimo, Metzendorf, Christoph, Monroe, Kristine, Pacolet, Alexander, Pérusse, Louis, Pool, Rene, Richmond, Rebecca, Rivera, Natalia, Robiou-du-Pont, Sebastien, Schraut, Katharina, Schulz, Christina-Alexandra, Stringham, Heather, Tanaka, Toshiko, Teumer, Alexander, Turman, Constance, van der Most, Peter, Vanmunster, Mathias, van Rooij, Frank, van Vliet-Ostaptchouk, Jana, Zhang, Xiaoshuai, Zhao, Jing-Hua, Zhao, Wei, Balkhiyarova, Zhanna, Balslev-Harder, Marie, Baumeister, Sebastian, Beilby, John, Blangero, John, Boomsma, Dorret, Brage, Soren, Braund, Peter, Brody, Jennifer, Bruinenberg, Marcel, Ekelund, Ulf, Liu, Ching-Ti, Cole, John, Collins, Francis, Cupples, L, Esko, Tõnu, Enroth, Stefan, Faul, Jessica, Fernandez-Rhodes, Lindsay, Fohner, Alison, Franco, Oscar, Galesloot, Tessel, Gordon, Scott, Grarup, Niels, Hartman, Catharina, Heiss, Gerardo, Hui, Jennie, Illig, Thomas, Jago, Russell, James, Alan, Joshi, Peter, Jung, Taeyeong, Kähönen, Mika, Kilpeläinen, Tuomas, Koh, Woon-Puay, and Kolcic, Ivana

Subjects
Actinin, Cross-Sectional Studies, Exercise, Genome-Wide Association Study, Humans, Leisure Activities, Sedentary Behavior
Abstract

Although physical activity and sedentary behavior are moderately heritable, little is known about the mechanisms that influence these traits. Combining data for up to 703,901 individuals from 51 studies in a multi-ancestry meta-analysis of genome-wide association studies yields 99 loci that associate with self-reported moderate-to-vigorous intensity physical activity during leisure time (MVPA), leisure screen time (LST) and/or sedentary behavior at work. Loci associated with LST are enriched for genes whose expression in skeletal muscle is altered by resistance training. A missense variant in ACTN3 makes the alpha-actinin-3 filaments more flexible, resulting in lower maximal force in isolated type IIA muscle fibers, and possibly protection from exercise-induced muscle damage. Finally, Mendelian randomization analyses show that beneficial effects of lower LST and higher MVPA on several risk factors and diseases are mediated or confounded by body mass index (BMI). Our results provide insights into physical activity mechanisms and its role in disease prevention.

Published
2022

38. Defining Global Benchmarks for Laparoscopic Right Posterior Sectionectomy/H67: An International Multicenter Study

Author

Zhao, Jianping, Lu, Yuanxiang, Zhang, Wanguang, Chua, Darren W., Liu, Qu, Liu, Rong, Pratschke, Johann, Ratti, Francesca, Zimmitti, Giuseppe, Aghayan, Davit L., Edwin, Bjørn, Siow, Tiing-Foong, Scatton, Olivier, Herman, Paulo, Marino, Marco V., Mazzaferro, Vincenzo, Chiow, Adrian K. H., Sucandy, Iswanto, Ivanecz, Arpad, Choi, Sung Hoon, Lee, Jae Hoon, Gastaca, Mikel, Vivarelli, Marco, Giuliante, Felice, Ruzzenente, Andrea, Yong, Chee-Chien, Yin, Mengqiu, Fondevila, Constantino, Efanov, Mikhail, Morise, Zenichi, Di Benedetto, Fabrizio, Brustia, Raffaele, Dalla Valle, Raffaele, Boggi, Ugo, Geller, David, Belli, Andrea, Memeo, Riccardo, Mejia, Alejandro, Park, James O., Rotellar, Fernando, Choi, Gi-Hong, Robles-Campos, Ricardo, Wang, Xiaoying, Sutcliffe, Robert P., Lai, Eric C. H., Chong, Charing C. N., D’Hondt, Mathieu, Monden, Kazuteru, Lopez-Ben, Santiago, Kingham, T. Peter, Ferrero, Alessandro, Ettorre, Giuseppe Maria, Cherqui, Daniel, Liang, Xiao, Soubrane, Olivier, Fuks, David, Wakabayashi, Go, Troisi, Roberto I., Cheung, Tan-To, Sugioka, Atsushi, Long, Tran Cong duy, Abu Hilal, Mohammad, Aldrighetti, Luca, Chen, Kuo-Hsin, Han, Ho-Seong, Goh, Brian K. P., Prieto, Mikel, De Meyere, Celine, Meurs, Juul, Ng, Kelvin K., Lee, Kit-Fai, Tarakanov, Pavel, Alikhanov, Ruslan, Thiruchelvam, Nita, Jang, Jae Young, Kojima, Masayuki, Kato, Yutaro, Kruger, Jaime Arthur Pirola, Coelho, Fabricio Ferreira, Lopez-Lopez, Victor, Casellas I Robert, Margarida, Montalti, Roberto, Giglio, Mariano, Lee, Boram, Wang, Hao-Ping, Salleh, Mansour, Pascual, Franco, Yu, Shian, Chen, Zewei, Vani, Simone, Ardito, Francesco, Giustizieri, Ugo, Citterio, Davide, Mocchegiani, Federico, Colasanti, Marco, Berardi, Giammauro, Guzmán, Yoelimar, Labadie, Kevin P., Conticchio, Maria, Dogeas, Epameinondas, Kauffmann, Emanuele F., Giuffrida, Mario, Sommacale, Daniele, Amory, Boris, Magistri, Paolo, Mishima, Kohei, Kadam, Prashant, Tang, Chung-Ngai, Ghotbi, Jacob, Fretland, Åsmund Avdem, Forchino, Fabio, Mazzotta, Alessandro, Barbara, Marco, Pagano, Duilio, Gruttadauria, Salvatore, Krenzien, Felix, Schmelzle, Moritz, Cipriani, Federica, Lim, Chetana, Zheng, Junhao, Nghia, Phan Phuoc, Valle, Bernardo Dalla, and Cipriani, Federica

Published
2024
Full Text
View/download PDF

39. Expanding Selection Criteria in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Long-term Follow-up of a National Registry and 2 Transplant Centers

Author

Wehrle, Chase J, Kusakabe, Jiro, Akabane, Miho, Maspero, Marianna, Zervos, Bobby, Modaresi Esfeh, Jamak, Whitsett Linganna, Maureen, Imaoka, Yuki, Khalil, Mazhar, Pita, Alejandro, Kim, Jaekeun, Diago-Uso, Teresa, Fujiki, Masato, Eghtesad, Bijan, Quintini, Cristiano, Kwon, Choon David, Pinna, Antonio, Aucejo, Federico, Miller, Charles, Mazzaferro, Vincenzo, Schlegel, Andrea, Sasaki, Kazunari, and Hashimoto, Koji

Published
2024
Full Text
View/download PDF

40. Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study

Author

Vitale, Alessandro, Trapani, Silvia, Russo, Francesco Paolo, Miele, Luca, Svegliati Baroni, Gianluca, Marchesini, Giulio, Burra, Patrizia, Ottoveggio, Marco Salvatore, Romagnoli, Renato, Martini, Silvia, De Simone, Paolo, Carrai, Paola, Cescon, Matteo, Morelli, Maria Cristina, De Carlis, Luciano, Belli, Luca, Gruttadauria, Salvatore, Volpes, Riccardo, Colledan, Michele, Fagiuoli, Stefano, Di Benedetto, Fabrizio, De Maria, Nicola, Rossi, Giorgio, Caccamo, Lucio, Donato, Francesca, Vennarecci, Giovanni, Di Costanzo, Giovan Giuseppe, Vivarelli, Marco, Carraro, Amedeo, Sacerdoti, David, Ettorre, Giuseppe Maria, Giannelli, Valerio, Agnes, Salvatore, Gasbarrini, Antonio, Rossi, Massimo, Ginanni Corradini, Stefano, Mazzaferro, Vincenzo, Bhoori, Sherrie, Manzia, Tommaso Maria, Lenci, Ilaria, Zamboni, Fausto, Mameli, Laura, Baccarani, Umberto, Toniutto, Pierluigi, Lupo, Luigi Giovanni, Tandoi, Francesco, Rendina, Maria, Andorno, Enzo, Giannini, Edoardo Giovanni, Spada, Marco, Billato, Ilaria, Marchini, Andrea, Romano, Pierluigi, Brancaccio, Giuseppina, D’Amico, Francesco, Ricci, Andrea, Cardillo, Massimo, and Cillo, Umberto

Published
2024
Full Text
View/download PDF

42. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

Author

Sara Pusceddu, Francesca Corti, Natalie Prinzi, Federico Nichetti, Silva Ljevar, Adele Busico, Tommaso Cascella, Rita Leporati, Simone Oldani, Chiara Carlotta Pircher, Jorgelina Coppa, Veronica Resi, Massimo Milione, Marco Maccauro, Rosalba Miceli, Elena Tamborini, Federica Perrone, Carlo Spreafico, Monica Niger, Federica Morano, Filippo Pietrantonio, Ettore Seregni, Luigi Mariani, Vincenzo Mazzaferro, Giorgia Di Liberti, Giovanni Fucà, Filippo de Braud, and Claudio Vernieri

Subjects
Well-differentiated neuroendocrine tumors (WDNETs), Metformin plus lanreotide, Safety, Antitumor activity, Phase Ib trial, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract In retrospective studies, metformin use has been associated with better clinical outcomes in diabetic patients with advanced, well-differentiated neuroendocrine tumors (WDNETs). However, prospective evidence of metformin safety and activity is lacking. Here, we conducted the first-in-human phase Ib MetNET2 trial to investigate the safety and antitumor activity of metformin in combination with the somatostatin analog lanreotide autogel (ATG) in both diabetic and non-diabetic patients with advanced WDNETs of the gastrointestinal (GI) or thoracic tract. Enrolled patients received lanreotide ATG 120 mg plus oral metformin, up to a maximum dosage of 2550 mg/day. We enrolled 20 patients, of whom 18 (90%) and 2 (10%) had WDNETs of the GI and thoracic tract, respectively. Fourteen patients (70%) were non-diabetic. With a 5% incidence of SAEs, the study met its primary objective of demonstrating treatment safety. With a median follow-up of 39 months (95% CI 28-NE), median PFS was 24 months (95% CI 16-NE), with 12-month and 24-month PFS probability of 75% (95% CI 58–97) and 49% (95% CI 31–77), respectively. We found no statistically significant PFS differences between diabetic and non-diabetic patients. Among exploratory analyses, the presence of tumor genomic alterations in DNA damage pathways was associated with trend towards worse PFS, whereas a precocious reduction of HOMA-IR index and plasma cholesterol concentration showed a trend towards an association with better PFS. In conclusion, metformin plus lanreotide ATG is a safe and well tolerated combination treatment that is associated with promising antitumor activity in both non-diabetic and diabetic patients with WDNETs, and that warrants further investigation in larger clinical trials.

Published
2023
Full Text
View/download PDF

45. Evolution of minimally invasive techniques and surgical outcomes of ALPPS in Italy: a comprehensive trend analysis over 10 years from a national prospective registry

Author

Serenari, Matteo, Ratti, Francesca, Guglielmo, Nicola, Zanello, Matteo, Mocchegiani, Federico, Lenzi, Jacopo, Colledan, Michele, Mazzaferro, Vincenzo, Cillo, Umberto, Ferrero, Alessandro, Cescon, Matteo, Di Benedetto, Fabrizio, Massani, Marco, Grazi, Gianluca, Valle, Raffaele Dalla, Vivarelli, Marco, Ettorre, Giuseppe Maria, Aldrighetti, Luca, and Jovine, Elio

Published
2023
Full Text
View/download PDF

46. Impact of neoadjuvant chemotherapy on short-term outcomes after simple and complex minimally invasive minor hepatectomy for colorectal liver metastases: A propensity-score matched and coarsened exact matched study

Author

Syn, Nicholas L., Prieto, Mikel, Meurs, Juul, De Meyere, Celine, Lee, Kit-Fai, Ng, Kelvin K., Salimgereeva, Diana, Alikhanov, Ruslan, Thiruchelvam, Nita, Jang, Jae Young, Kato, Yutaro, Kojima, Masayuki, Coelho, Fabricio Ferreira, Pirola Kruger, Jaime Arthur, Lopez-Lopez, Victor, Casellas I Robert, Margarida, Montalti, Roberto, Giglio, Mariano, Lee, Boram, D'Silva, Mizelle, Wang, Hao-Ping, Saleh, Mansour, Pascual, Franco, Chen, Zewei, Yu, Shian, Vani, Simone, Ardito, Francesco, Giustizieri, Ugo, Citterio, Davide, Mocchegiani, Federico, Colasanti, Marco, Berardi, Giammauro, Guzmán, Yoelimar, Labadie, Kevin P., Conticchio, Maria, Dogeas, Epameinondas, Kauffmann, Emanuele F., Giuffrida, Mario, Sommacale, Daniele, Laurent, Alexis, Magistri, Paolo, Nghia, Phan Phuoc, Mishima, Kohei, Valle, Bernardo Dalla, Krenzien, Felix, Schmelzle, Moritz, Kadam, Prashant, Liu, Qu, Lai, Eric C.H., Zheng, Junhao, Siow, Tiing Foong, Forchino, Fabio, Ghotbi, Jacob, Fretland, Åsmund A., Lim, Chetana, Mazzotta, Alessandro, Cauchy, Francois, Karam, Elias, Barbara, Marco, Pagano, Duilio, Ratti, Francesca, Hoogteijling, Tijs J., Abu Hilal, Mohammad, Zimmitti, Giuseppe, Aghayan, Davit L., Wu, Andrew G.R., Cipriani, Federica, Gruttadauria, Salvatore, Scatton, Olivier, Long, Tran Cong duy, Herman, Paulo, Marino, Marco V., Mazzaferro, Vincenzo, Chiow, Adrian K.H., Sucandy, Iswanto, Ivanecz, Arpad, Choi, Sung Hoon, Lee, Jae Hoon, Gastaca, Mikel, Vivarelli, Marco, Giuliante, Felice, Ruzzenente, Andrea, Yong, Chee Chien, Yin, Mengqiu, Fondevila, Constantino, Efanov, Mikhail, Morise, Zenichi, Di Benedetto, Fabrizio, Brustia, Raffaele, Dalla Valle, Raffaele, Boggi, Ugo, Geller, David, Belli, Andrea, Memeo, Riccardo, Mejia, Alejandro, Park, James O., Rotellar, Fernando, Choi, Gi Hong, Robles-Campos, Ricardo, Wang, Xiaoying, Sutcliffe, Robert P., Pratschke, Johann, Tang, Chung-Ngai, Chong, Charing C.N., D'Hondt, Mathieu, Monden, Kazuteru, Lopez-Ben, Santiago, Kingham, T. Peter, Ferrero, Alessandro, Ettorre, Giuseppe Maria, Cherqui, Daniel, Liang, Xiao, Soubrane, Olivier, Wakabayashi, Go, Troisi, Roberto I., Han, Ho Seong, Cheung, Tan To, Sugioka, Atsushi, Dokmak, Safi, Chen, Kuo Hsin, Liu, Rong, Fuks, David, Zhang, Wanguang, Aldrighetti, Luca, Edwin, Bjørn, and Goh, Brian K.P.

Published
2024
Full Text
View/download PDF

49. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Author

Reig, Maria, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Kelley, Robin K, Galle, Peter R, Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G, Vogel, Arndt, Fuster, Josep, Ayuso, Carmen, and Bruix, Jordi

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Rare Diseases, Liver Disease, Liver Cancer, Digestive Diseases, Clinical Trials and Supportive Activities, Good Health and Well Being, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Severity of Illness Index, HCC, survival, BCLC, ablation, surgery, liver transplantation TACE, TARE, systemic treatment, ALBI score, AFP, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results